In contrast, the TP53, RB1 and ATM cell cycle checkpoint genes showed a significantly higher rate of mutations in carcinomas (42/60; 70.0%) than in carcinoids (9/88; 10.2%; p < 0.0001; Figure 4). This evidence concerns the gene RB1 and carcinoid tumor.